Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
88
-
Total 13F shares, excl. options
-
19.2M
-
Shares change
-
-4.24M
-
Total reported value, excl. options
-
$93.6M
-
Value change
-
-$55.2M
-
Number of buys
-
43
-
Number of sells
-
-55
-
Price
-
$4.88
Significant Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) as of Q4 2022
116 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q4 2022.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.2M shares
of 45.1M outstanding shares and own 42.53% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.58M shares), VANGUARD GROUP INC (2.26M shares), Sofinnova Investments, Inc. (2.19M shares), Polar Capital Holdings Plc (1.99M shares), MILLENNIUM MANAGEMENT LLC (1.13M shares), CITADEL ADVISORS LLC (960K shares), STATE STREET CORP (832K shares), GEODE CAPITAL MANAGEMENT, LLC (631K shares), AQR CAPITAL MANAGEMENT LLC (480K shares), and D. E. Shaw & Co., Inc. (469K shares).
This table shows the top 88 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.